SOPHiA GENETICS SA (SOPH) Q4 2025 Earnings Call Transcript

Why It Matters

The results demonstrate SOPHiA's ability to scale AI‑enabled genomics services profitably, positioning it as a critical data partner for biopharma and accelerating its path to sustainable growth.

Key Takeaways

• Revenue up 23% to $19.5M, third quarter acceleration
• U.S. revenue grew 30%, expanding market foothold
• Liquid biopsy analyses surged 300%, over 2,000 tests
• Net dollar retention reached 108%, indicating strong upsell
• Adjusted gross margin held at 73.1% despite volume rise

Pulse Analysis

SOPHiA GENETICS continues to cement its position as a leading AI‑powered genomics platform, reporting $19.5 million in Q4 2025 revenue—a 23 percent year‑over‑year increase and the third straight quarter of accelerating growth. The surge is driven by a record 31 new customer signings, expanding the client base to 94 this year, and a 30 percent jump in U.S. revenue that underscores deepening penetration in the most lucrative market. Stable adjusted gross margins at 73.1 percent demonstrate that the company can scale data‑intensive workloads without eroding profitability, a rare feat in the high‑growth health‑tech sector.

The launch of SOPHiA DDM Digital Twins and the rapid expansion of the MSK Access liquid‑biopsy suite signal a strategic shift toward multimodal AI diagnostics. Liquid‑biopsy analyses climbed more than 300 percent to exceed 2,000 tests, and the partnership with AstraZeneca—its largest biopharma contract to date—positions SOPHiA as a critical data source for companion‑diagnostic development. Additional collaborations with Myriad Genetics in the United States and ADAM Innovations in Japan broaden the regulatory footprint, enabling a hybrid global CDx offering that could accelerate drug development timelines while delivering cost‑effective testing to patients worldwide.

Financially, SOPHiA reported an operating loss of $17.9 million, widened by one‑off legal and Swiss social‑tax expenses, yet cash reserves remain robust at $81.6 million with a $13.1 million quarterly burn. Management lifted full‑year revenue guidance to $75‑$77 million, targeting 15‑18 percent growth, and reaffirmed a net‑dollar‑retention rate of 108 percent, underscoring the effectiveness of its land‑and‑expand model. While a patent lawsuit from Guardant Health and a stronger Swiss franc pose short‑term headwinds, the expanding backlog and pipeline—now the highest in company history—provide confidence that the firm can sustain momentum into 2026 and beyond.